Comparing Single-Dose and Multiple-Dose Designs in Bioequivalence Trials

Introduction: Why Dosing Strategy Matters in BA/BE Trials

In bioequivalence (BE) trials, the decision to conduct a single-dose or multiple-dose study impacts not only the study duration and complexity but also its scientific validity and regulatory acceptance. The key objective of a BE study is to demonstrate that the Test and Reference formulations exhibit comparable pharmacokinetics (PK). How many doses are administered—and under what conditions—can significantly affect PK parameters such as C_max, AUC_0–t, and T_max.

Regulatory agencies such as the Australian New Zealand Clinical Trials Registry (ANZCTR), FDA, EMA, and CDSCO provide detailed guidance on choosing between single and multiple dosing. Factors include the drug’s pharmacokinetics, dosage form, intended clinical use, and safety profile.

Single-Dose Bioequivalence Studies: The Global Standard

Single-dose studies are the most widely used form of BE trials, especially for immediate-release (IR) formulations. In such studies, a single administration of the Test and Reference product is compared in healthy volunteers under fasting or fed conditions. This design simplifies interpretation and minimizes variables.

Key advantages:

• Lower risk and shorter study duration
• More straightforward PK analysis
• Smaller sample size
• Lower cost and easier ethics board approval

Single-dose designs are sufficient for most generic applications unless the drug demonstrates time-dependent pharmacokinetics, shows accumulation, or is intended for chronic use with delayed pharmacodynamic effects.

When Are Multiple-Dose Studies Necessary?

Multiple-dose BE studies are typically conducted when steady-state conditions are required to reflect therapeutic usage, especially for drugs with long half-lives, significant accumulation, or modified-release formulations. These studies help assess systemic exposure over time and ensure bioequivalence at steady state.

Scenarios requiring multiple-dose studies:

• Drug has a long half-life (e.g., ≥ 24 hours)
• Chronic administration is standard therapy
• Therapeutic action is due to steady-state exposure
• Drug exhibits time-dependent metabolism
• Modified-release (MR) or controlled-release (CR) formulations

Multiple-dose studies are longer, more complex, and require careful monitoring of safety, compliance, and PK sampling schedules to ensure accurate determination of steady state and accumulation ratios.

Key Pharmacokinetic Parameters: Single vs Steady State

In multiple-dose studies, additional parameters such as Accumulation Ratio (R_ac) and Time to Steady State are also critical for regulatory assessments.

Design Considerations for Multiple-Dose Trials

Conducting a multiple-dose study requires careful planning:

• Multiple dosing until steady state (≥ 5 half-lives)
• Confirmation of steady state using pre-dose trough concentrations (C_min)
• Serial PK sampling during the final dosing interval
• Close monitoring of adverse events

For instance, a drug with a half-life of 36 hours may require 7–10 days of dosing before reaching steady state. This demands both subject compliance and logistical coordination across clinical, analytical, and data management teams.

Regulatory Preferences and Guidance

Most regulatory agencies prefer single-dose studies unless multiple-dosing is clinically justified. The FDA’s “Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products” recommends single-dose studies unless steady-state data are critical for demonstrating equivalence.

The EMA states in its guideline: “A single-dose study is generally sufficient to demonstrate bioequivalence. A multiple-dose study may be necessary for modified-release formulations or if the drug shows non-linear pharmacokinetics.”

CDSCO (India) follows similar lines and expects clear justification in the protocol if multiple-dose trials are proposed, including safety monitoring, ECGs, and liver/kidney function tests.

Case Study: Multiple-Dose BE Study for a Once-Daily Antidepressant

A sponsor planned a BE study for a once-daily controlled-release formulation of paroxetine with a half-life of ~21 hours. The FDA required a multiple-dose study to demonstrate bioequivalence under steady-state conditions.

Study Design:

• Design: Randomized, multiple-dose, two-period, two-sequence crossover
• Dosing: Once daily for 7 days
• PK Sampling: 0 to 24 hours post-dose on Day 7
• Evaluation: AUC_τ, C_max,ss, T_max, Fluctuation Index
• Result: 90% CI within 80.00–125.00%, BE demonstrated

When Single and Multiple Dose Studies Are Both Required

In some regulatory submissions, both single and multiple dose studies may be mandated. This typically occurs for modified-release products or drugs with complex PK profiles. Additionally, separate fed and fasting condition studies may be required alongside multiple dosing evaluations.

In such scenarios, sequencing of studies, washout periods, and subject burden become critical considerations. CROs must have capabilities for parallel planning, adaptive logistics, and contingency management.

Conclusion: Selecting the Optimal Dose Regimen for BE Assessment

Choosing between a single-dose and multiple-dose design in BA/BE trials is a nuanced decision that must align with pharmacokinetic principles, therapeutic indications, and regulatory frameworks. While single-dose studies remain the standard, multiple-dose studies are indispensable in select circumstances—particularly when assessing steady-state performance or accumulation risks.

By integrating data from global regulatory guidance and tailoring study designs to drug characteristics, sponsors can streamline approval timelines, reduce development costs, and ensure scientific integrity.